Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tafalgie Therapeutics

Request full access

Next-generation pain management treatments derived from an endogenous secreted protein capable of modulating pain signals

Marseille, FranceFounded 2020Biotech & Life Sciences

About Tafalgie Therapeutics

Tafalgie Therapeutics is a French biopharmaceutical startup that specializes in the development of non-opioid drugs for the treatment of chronic, severe, or persistent pain. The company is a spin-off from the French National Centre for Scientific Research (CNRS) and Aix-Marseille University (AMU). Their primary focus is on creating a new scientific approach for next-generation treatments, which are based on an innovative mechanism of action derived from a protein capable of modulating pain signals. This is a significant breakthrough in the medical field, especially considering the current opioid crisis.

Tafalgie Therapeutics serves a broad range of clients, including patients suffering from acute severe pain and chronic refractory pain. The company operates in the global pharmaceutical market, which is expected to reach $100 billion by 2030. Their business model revolves around the research, development, and commercialization of their unique, non-addictive pain relief drugs.

The company generates revenue through the sale of these drugs, which are designed to provide high-efficacy, high-tolerability, and non-addictive solutions for pain management. They are also dedicated to the prevention and treatment of chronic refractory pain, a condition that is often inadequately treated.

In summary, Tafalgie Therapeutics is a promising startup in the pharmaceutical industry, with a unique approach to pain management that could revolutionize the treatment of chronic and severe pain.

Source: Dealroom company data

At a glance

Status
Operational
Employees
29
Open positions
None listed
Dealroom signal
88.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Rehabilitation, Biotechnology, Spinout, EIC, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Horizon Europe
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Sep 2025 $13M $53M Bpifrance ↗
GRANT✓Other financing Jun 2023 $2.5M — European Innovation Council —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Tafalgie Therapeutics website traffic

Latest recorded traffic for Tafalgie Therapeutics is 1.6K monthly website visits, up 63.3% over the last three months. Tafalgie Therapeutics's team grew 26.1% over the past year.

Latest monthly visits1.6K 3-month web change+63.3% 1-year team growth+26.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Tafalgie Therapeutics in the Marseille ecosystem

Live from Dealroom

The Tafalgie Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Laurent Labatut
  • Eric Schettini
  • European Innovation Council

Series A1 investor entered at this stage

Other known investors5 additional known investors

  • CNRS Innovation
  • French National Centre for Scientific Research - CNRS
  • Incubateur Impulse
  • SATT Sud-Est
  • ROC Global Opportunities
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇫🇷 France90.9%
🇱🇺 Luxembourg4.5%
🇪🇸 Spain4.5%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tafalgie Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tafalgie Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.